ArticleCureus2025
Association of Coenzyme Q10 Supplementation With Statin-Associated Muscle Symptoms in Long-Term Statin Users.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionStatins are among the most commonly prescribed medications for lowering blood cholesterol levels and are considered safe and effective. However, statin-associated muscle symptoms (SAMS) remain a frequent adverse effect encountered in clinical settings.
objectiveTo compare the effectiveness of coenzyme Q10 (CoQ10) with no supplementation in the management of statin-associated muscle symptoms among patients on statin therapy.
methodsThis observational study was conducted in the Department of Medicine at the Pakistan Institute of Medical Sciences (PIMS), Shaheed Zulfiqar Ali Bhutto Medical University (SZABMU), Islamabad, over a period of six months following ethical approval. A total of 106 patients with clinically identified SAMS were included. Group A (n=53) comprised patients who received CoQ10 (50 mg twice daily), while Group B (n=53) included patients who received no supplementation and were managed conservatively. Results: Patients in Group A who received CoQ10 showed a greater reduction in both VAS and pain interference scores compared to Group B. The differences between the two groups were statistically significant (p = 0.001), suggesting better symptom control in the CoQ10 group.
conclusionCoQ10 supplementation (50 mg twice daily) was associated with improved control of statin-associated muscle symptoms in an observational clinical setting. These findings support its potential role as an adjunctive option for patients experiencing muscle-related side effects from statin therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.